DECEMBER 2023LIFE SCIENCES REVIEW6Cancer immunotherapy has emerged as a promising approach for treating cancer over the past decade. Some key trends include the development of checkpoint inhibitor drugs like PD-1 and CTLA-4 inhibitors that help activate the immune system against cancer cells. Another trend is utilizing CAR T-cell therapy, which involves genetically engineering a patient's own T-cells to recognize and kill cancer. That said, combination immunotherapies using multiple immune-based treatments together are becoming the talk of the town now, as combinations can be more effective than single agents alone. Its significant progress and promising clinical results is bringing new hope for more effective and less toxic cancer treatments. Driven by these trends, the global cancer immunotherapy market is expected to surpass $674 billion by 2032, growing at a CAGR of 13.8 percent globally. This edition of Life Sciences Review APAC brings insights into the latest developments in cancer immunotherapy and how companies adopting transformative therapies are shaping the future of cancer care.It features a thought leadership article from James Riddle, Vice President, Research Services and Strategic Consulting at Advarra, who expresses his optimistic views about the future of immunotherapy beyond cancer, and encourages the industry to proactively develop the infrastructure and skills to make personalized immunotherapies a reality for patients. It also features an article from Robert Zanon, General Manager, Quality at Probiotec, who talks about the increasing regulatory requirements and scientific sophistication involved in pharmaceutical cleaning validations. In this edition of Life Sciences Review APAC, we also bring you the story of the top cancer immunotherapy companies constantly striving toward developing novel cancer cures that effectively treat patients while minimizing side effects. One of them is Cytek® Biosciences, Inc. which develops advanced flow cytometry tools and technologies to enable researchers unlock insights in cell analysis for advanced cancer immunotherapy and translational research applications.In this edition featuring the top cancer immunotherapy companies in APAC 2023, we hope you find the right partner to meet your organization's needs.Let us know your thoughts!EDITORIALCombination Immunotherapies for Enhanced Patient CareCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsDecember - 12 - 2023, Vol 04, Issue - 62 ( ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersEmail:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.comAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoCelestial Jordan
< Page 5 | Page 7 >